Asha Therapeutics LLC
Asha Therapeutics is a biopharmaceutical company focused on developing disease-modifying and curative therapeutics for neurodegenerative, neurological, and infectious diseases with high unmet medical need. Leveraging its proprietary PRISM™ technology, the company designs de novo compounds targeting difficult-to-drug disease targets, aiming to transform patient outcomes with innovative medicines.
Industries
Nr. of Employees
small (1-50)
Asha Therapeutics LLC
Tampa, Florida, United States, North America
Products
SARM1 inhibitor (intramolecular glue) — development candidate
A first-in-class intramolecular glue small molecule designed to stabilize SARM1 in an inactive conformation to prevent axonal degeneration; demonstrated robust preclinical neuroprotection in animal models and being advanced as IND-enabling candidate for ALS, chemotherapy-induced peripheral neuropathy, retinal and other neurodegenerative indications.
DRP1 inhibitor — brain-penetrant mitochondrial dynamics modulator
A selective, brain-penetrant small molecule designed to modulate mitochondrial fission/fusion dynamics (DRP1 inhibition) to restore mitochondrial homeostasis and limit neurodegeneration; shown efficacious in preclinical models of Alzheimer's and Parkinson's disease and advanced as an IND-enabling candidate.
E3 ligase recruiter chemistry for targeted protein degradation
Small-molecule recruiter chemistry optimized for the VHL E3 ligase to enable targeted protein degradation approaches with improved pharmacokinetic and drug-like properties.
SARM1 inhibitor (intramolecular glue) — development candidate
A first-in-class intramolecular glue small molecule designed to stabilize SARM1 in an inactive conformation to prevent axonal degeneration; demonstrated robust preclinical neuroprotection in animal models and being advanced as IND-enabling candidate for ALS, chemotherapy-induced peripheral neuropathy, retinal and other neurodegenerative indications.
DRP1 inhibitor — brain-penetrant mitochondrial dynamics modulator
A selective, brain-penetrant small molecule designed to modulate mitochondrial fission/fusion dynamics (DRP1 inhibition) to restore mitochondrial homeostasis and limit neurodegeneration; shown efficacious in preclinical models of Alzheimer's and Parkinson's disease and advanced as an IND-enabling candidate.
E3 ligase recruiter chemistry for targeted protein degradation
Small-molecule recruiter chemistry optimized for the VHL E3 ligase to enable targeted protein degradation approaches with improved pharmacokinetic and drug-like properties.
Services
Physics-based molecular design platform partnerships
Partnership access to a physics-based molecular design platform for target assessment, de novo compound design, and chemistry optimization to accelerate candidate generation and reduce screening needs.
Preclinical development and translational collaboration
Collaborative preclinical programs including testing in patient-derived cells and animal models, study design support, and IND-enabling research for neurological and rare diseases.
Physics-based molecular design platform partnerships
Partnership access to a physics-based molecular design platform for target assessment, de novo compound design, and chemistry optimization to accelerate candidate generation and reduce screening needs.
Preclinical development and translational collaboration
Collaborative preclinical programs including testing in patient-derived cells and animal models, study design support, and IND-enabling research for neurological and rare diseases.
Expertise Areas
- Computational drug design
- Small-molecule medicinal chemistry
- Neurodegenerative disease therapeutics development
- Targeted protein degradation (TPD)
Key Technologies
- Physics-based molecular simulation
- De novo small-molecule design
- Intramolecular glue modality
- E3 ligase recruiter chemistry for TPD